Inositol phosphates and phosphoinositides in health and disease

Sub-Cellular Biochemistry

Volumn 39, Issue , 2006, Pages 263-290

  Shi, Yihui ^a   Azab, Abed N ^a   Thompson, Morgan N ^a   Greenberg, Miriam L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934876809     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (170)

1. Addis, M., Loi, M., Lepiani, C., Cau, M., and Melis, M. A., 2004, OCRL mutation analysis in Italian patients with Lowe syndrome. Hum. Mutat. 23: 524-525.
2. Aisen, P. S., 1997, Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontology 43: 143-149.
3. Atack, J. R., 2000, Lithium, phosphatidylinositol signaling, and bipolar disorder. In: Manji, H. K., Bowden, C. L., and Belmaker, R. H. (eds.), Bipolar Medications: Mechanism of Action. American Psychiatric Press, Inc., Washington, DC.
4. Attree, O., Olivos, I. M., Okabe, I., Bailey, L. C., Nelson, D. L., Lewis, R. A., McInnes, R. R., and Nussbaum, R. L., 1992, The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 358: 239-242.
5. Azzedine, H., Bolino, A., Taieb, T., Birouk, N., Di Duca, M., Bouhouche, A., Benamou, S., Mrabet, A., Hammadouche, T., Chkili, T., Gouider, R., Ravazzolo, R., Brice, A., Laporte, J., and LeGuern, E., 2003, Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am. J. Hum. Genet. 72: 1141-1153.
6. Bachhawat, N., and Mande, S. C., 1999, Identification of the INO1 gene of Mycobacterium tuberculosis H37Rv reveals a novel class of inositol-1-phosphate synthase enzyme. J. Mol. Biol. 291: 531-536.
7. Baumann, C. A., Ribon, V., Kanzaki, M., Thurmond, D. C., Mora, S., Shigematsu, S., Bickel, P. E., Pessin, J. E., and Saltiel, A. R., 2000, CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407: 202-207.
8. Belmaker, R. H., 2004, Bipolar disorder. N. Engl. J. Med. 351: 476-486.
9. Berger, P., Bonneick, S., Willi, S., Wymann, M., and Suter, U., 2002, Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1. Hum. Mol. Genet. 11: 1569-1579.
10. Berridge, M. J., 1987, Inositol trisphosphate and diacylglycerol: Two interacting second messengers. Annu. Rev. Biochem. 56: 159-193.
11. Berridge, M. J., 1993, Inositol trisphosphate and calcium signalling. Nature 361: 315-325.
12. Berridge, M. J., Downes, C. P., and Hanley, M. R., 1982, Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 206: 587-595.
13. Berridge, M. J., and Irvine, R. F., 1989, Inositol phosphates and cell signalling. Nature 341: 197-205.
14. Blero, D., De Smedt, F., Pesesse, X., Paternotte, N., Moreau, C., Payrastre, B., and Erneux, C., 2001, The SH2 domain containing inositol 5-phosphatase SHIP2 controls phosphatidylinositol 3, 4, 5-trisphosphate levels in CHO-IR cells stimulated by insulin. Biochem. Biophys. Res. Commun. 282: 839-843.
15. Blondeau, F., Laporte, J., Bodin, S., Superti-Furga, G., Payrastre, B., and Mandel, J. L., 2000, Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum. Mol. Genet. 9: 2223-2229.
16. Bloom, F. E., 2001, Neurotransmission and the central nervous system. In: Hradman, J. G., Limbird, L. E., and Gilman, A. G. (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., Section III, Chapter 12. The McGraw-Hill companies.
17. Bolino, A., Muglia, M., Conforti, F. L., LeGuern, E., Salih, M. A., Georgiou, D. M., Christodoulou, K., Hausmanowa-Petrusewicz, I., Mandich, P., Schenone, A., Gambardella, A., Bono, F., Quattrone, A., Devoto, M., and Monaco, A. P., 2000, Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat. Genet. 25: 17-19.
18. Brookmeyer, R., Gray, S., and Kawas, C., 1998, Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88: 1337-1342.
19. Buj-Bello, A., Laugel, V., Messaddeq, N., Zahreddine, H., Laporte, J., Pellissier, J. F., and Mandel, J. L., 2002, The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 99: 15060-15065.
20. Calera, M. R., Martinez, C., Liu, H., Jack, A. K., Birnbaum, M. J., and Pilch, P. F., 1998, Insulin increases the association of Akt-2 with Glut4-containing vesicles. J. Biol. Chem. 273: 7201-7204.
21. Cantley, L. C., 2002, The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
22. Cantley, L. C., and Neel, B. G., 1999, New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96: 4240-4245.
23. Carman, G. M., and Henry, S. A., 1999, Phospholipid biosynthesis in the yeast Saccharomyces cerevisiae and interrelationship with other metabolic processes. Prog. Lipid Res. 38: 361-399.
24. Chen, G., Huang, L. D., Jiang, Y. M., and Manji, H. K., 1999a, The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72: 1327-1330.
25. Chen, G., Zeng, W. Z., Yuan, P. X., Huang, L. D., Jiang, Y. M., Zhao, Z. H., and Manji, H. K., 1999b, The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72: 879-882.
26. Chen, L., Zhou, C., Yang, H., and Roberts, M. F., 2000, Inositol-1-phosphate synthase from Archaeoglobus fulgidus is a class II aldolase. Biochemistry 39: 12415-12423.
27. Clement, S., Krause, U., Desmedt, F., Tanti, J. F., Behrends, J., Pesesse, X., Sasaki, T., Penninger, J., Doherty, M., Malaisse, W., Dumont, J. E., Le Marchand-Brustel, Y., Erneux, C., Hue, L., and Schurmans, S., 2001, The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409: 92-97.
28. Connolly, T. M., Bansal, V. S., Bross, T. E., Irvine, R. F., and Majerus, P. W., 1987, The metabolism of tris-and tetraphosphates of inositol by 5-phosphomonoesterase and 3-kinase enzymes. J. Biol. Chem. 262: 2146-2149.
29. de Gouyon, B. M., Zhao, W., Laporte, J., Mandel, J. L., Metzenberg, A., and Herman, G. E., 1997, Characterization of mutations in the myotubularin gene in twenty six patients with X-linked myotubular myopathy. Hum. Mol. Genet. 6: 1499-1504.
30. Deliliers, G. L., Servida, F., Fracchiolla, N. S., Ricci, C., Borsotti, C., Colombo, G., and Soligo, D., 2002, Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells. Br. J. Haematol. 117: 577-587.
31. Dressman, M. A., Olivos-Glander, I. M., Nussbaum, R. L., and Suchy, S. F., 2000, Ocrl1, a PtdIns(4, 5)P(2) 5-phosphatase, is localized to the trans-Golgi network of fibroblasts and epithelial cells. J. Histochem. Cytochem. 48: 179-190.
32. Druzijanic, N., Juricic, J., Perko, Z., and Kraljevic, D., 2002, IP-6 & inosito: Adjuvant chemotherapy of colon cancer. A pilot clinical trial. Rev. Oncologia 4: 171.
33. Efanov, A. M., Zaitsev, S. V., and Berggren, P. O., 1997, Inositol hexakisphosphate stimulates non-Ca2+-mediated and primes Ca2+-mediated exocytosis of insulin by activation of protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 94: 4435-4439.
34. Fox, C. H., and Eberl, M., 2002, Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: A systematic review. Complement. Ther. Med. 10: 229-234.
35. Freeburn, R. W., Wright, K. L., Burgess, S. J., Astoul, E., Cantrell, D. A., and Ward, S. G., 2002, Evidence that SHIP-1 contributes to phosphatidylinositol 3, 4, 5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J. Immunol. 169: 5441-5450.
36. Fujii, S., Matsumoto, M., Igarashi, K., Kato, H., and Mikoshiba, K., 2000, Synaptic plasticity in hippocampal CA1 neurons of mice lacking type 1 inositol-1, 4, 5-trisphosphate receptors. Learn. Mem. 7: 312-320.
37. Garlind, A., Cowburn, R. F., Forsell, C., Ravid, R., Winblad, B., and Fowler, C. J., 1995, Diminished [3H]inositol(1, 4, 5)P3 but not [3H]inositol(1, 3, 4, 5)P4 binding in Alzheimer's disease brain. Brain Res. 681: 160-166.
38. Geier, S. J., Algate, P. A., Carlberg, K., Flowers, D., Friedman, C., Trask, B., and Rohrschneider, L. R., 1997, The human SHIP gene is differentially expressed in cell lineages of the bone marrow and blood. Blood 89: 1876-1885.
39. Gould, T. D., Einat, H., Bhat, R., and Manji, H. K., 2004c, AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 1-4.
40. Gould, T. D., Quiroz, J. A., Singh, J., Zarate, C. A., and Manji, H. K., 2004a, Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry 9: 734-755.
41. Gould, T. D., Zarate, C. A., and Manji, H. K., 2004b, Glycogen synthase kinase-3: A target for novel bipolar disorder treatments. J. Clin. Psychiatry. 65: 10-21.
42. Grases, F., Perello, J., Prieto, R. M., Simonet, B. M., and Torres, J. J., 2004, Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: A pilot study in Wistar rats. Life Sci. 75: 11-19.
43. Hallcher, L. M., and Sherman, W. R., 1980, The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255: 10896-10901.
44. Haug, L. S., Ostvold, A. C., Cowburn, R. F., Garlind, A., Winblad, B., Bogdanovich, N., and Walaas, S. I., 1996, Decreased inositol (1, 4, 5)-trisphosphate receptor levels in Alzheimer's disease cerebral cortex: Selectivity of changes and possible correlation to pathological severity. Neurodegeneration 5: 169-176.
45. Hawkins, P. T., Poyner, D. R., Jackson, T. R., Letcher, A. J., Lander, D. A., and Irvine, R. F., 1993, Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: A possible physiological function for myo-inositol hexakisphosphate. Biochem. J. 294(Pt 3): 929-934.
46. Helgason, C. D., Damen, J. E., Rosten, P., Grewal, R., Sorensen, P., Chappel, S. M., Borowski, A., Jirik, F., Krystal, G., and Humphries, R. K., 1998, Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12: 1610-1620.
47. Herman, G. E., Kopacz, K., Zhao, W., Mills, P. L., Metzenberg, A., and Das, S., 2002, Characterization of mutations in fifty North American patients with X-linked myotubular myopathy. Hum. Mutat. 19: 114-121.
48. Heslop, J. P., Irvine, R. F., Tashjian, A. H., Jr., and Berridge, M. J., 1985, Inositol tetrakis-and pentakisphosphates in GH4 cells. J. Exp. Biol. 119: 395-401.
49. Inhorn, R. C., and Majerus, P. W., 1988, Properties of inositol polyphosphate 1-phosphatase. J. Biol. Chem. 263: 14559-14565.
50. Irvine, R. F., Letcher, A. J., Lander, D. J., and Downes, C. P., 1984, Inositol trisphosphates in carbachol-stimulated rat parotid glands. Biochem. J. 223: 237-243.
51. Irvine, R. F., and Schell, M. J., 2001, Back in the water: The return of the inositol phosphates. Nat. Rev. Mol. Cell Biol. 2: 327-338.
52. Ismailov, II, Fuller, C. M., Berdiev, B. K., Shlyonsky, V. G., Benos, D. J., and Barrett, K. E., 1996, A biologic function for an "orphan" messenger: D-myo-inositol 3, 4, 5, 6-tetrakisphosphate selectively blocks epithelial calcium-activated chloride channels. Proc. Natl. Acad. Sci. U. S. A. 93: 10505-10509.
53. Jacobsen, A. N., Du, X. J., Lambert, K. A., Dart, A. M., and Woodcock, E. A., 1996, Arrhythmogenic action of thrombin during myocardial reperfusion via release of inositol 1, 4, 5-triphosphate. Circulation 93: 23-26.
54. Janne, P. A., Suchy, S. F., Bernard, D., MacDonald, M., Crawley, J., Grinberg, A., Wynshaw-Boris, A., Westphal, H., and Nussbaum, R. L., 1998, Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice. J. Clin. Invest. 101: 2042-2053.
55. Jope, R. S., 2003, Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24: 441-443.
56. Ju, S., Greenberg, M. L., in press, 1D-myo-inositol 3-phosphate synthase: Conversion, regulation, and putative target of mood stabilizers. Clin. Neurosci. Res.
57. Ju, S., Shaltiel, G., Shamir, A., Agam, G., and Greenberg, M. L., 2004, Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J. Biol. Chem. 279: 21759-21765.
58. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., and Eldar-Finkelman, H., 2004, Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry 55: 781-784.
59. Kanai, F., Ito, K., Todaka, M., Hayashi, H., Kamohara, S., Ishii, K., Okada, T., Hazeki, O., Ui, M., and Ebina, Y., 1993, Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. Biochem. Biophys. Res. Commun. 195: 762-768.
60. Kanzaki, M., and Pessin, J. E., 2003, Insulin signaling: GLUT4 vesicles exit via the exocyst. Curr. Biol. 13: R574-R576.
61. Katagiri, H., Asano, T., Ishihara, H., Inukai, K., Shibasaki, Y., Kikuchi, M., Yazaki, Y., and Oka, Y., 1996, Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J. Biol. Chem. 271: 16987-16990.
62. Kijima, Y., Saito, A., Jetton, T. L., Magnuson, M. A., and Fleischer, S., 1993, Different intracellular localization of inositol 1, 4, 5-trisphosphate and ryanodine receptors in cardiomyocytes. J. Biol. Chem. 268: 3499-3506.
63. Kitamura, N., Hashimoto, T., Nishino, N., and Tanaka, C., 1989, Inositol 1, 4, 5-trisphosphate binding sites in the brain: Regional distribution, characterization, and alterations in brains of patients with Parkinson's disease. J. Mol. Neurosci. 1: 181-187.
64. LaFerla, F. M., 2002, Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3: 862-872.
65. Laporte, J., Biancalana, V., Tanner, S. M., Kress, W., Schneider, V., Wallgren-Pettersson, C., Herger, F., Buj-Bello, A., Blondeau, F., Liechti-Gallati, S., and Mandel, J. L., 2000, MTM1 mutations in X-linked myotubular myopathy. Hum. Mutat. 15: 393-409.
66. Laporte, J., Blondeau, F., Buj-Bello, A., Tentler, D., Kretz, C., Dahl, N., and Mandel, J. L., 1998, Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human. Hum. Mol. Genet. 7: 1703-1712.
67. Laporte, J., Hu, L. J., Kretz, C., Mandel, J. L., Kioschis, P., Coy, J. F., Klauck, S. M., Poustka, A., and Dahl, N., 1996, A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 13: 175-182.
68. Larsson, O., Barker, C. J., Sj-oholm, A., Carlqvist, H., Michell, R. H., Bertorello, A., Nilsson, T., Honkanen, R. E., Mayr, G. W., Zwiller, J., and Berggren, P. O., 1997, Inhibition of phosphatases and increased Ca2+ channel activity by inositol hexakisphosphate. Science 278: 471-474.
69. Leung, A. Y., Wong, P. Y., Gabriel, S. E., Yankaskas, J. R., and Boucher, R. C., 1995, cAMP-but not Ca(2+)-regulated Cl-conductance in the oviduct is defective in mouse model of cystic fibrosis. Am. J. Physiol. 268: C708-C712.
70. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R., 1997, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
71. Liang, Y., Hua, Z., Liang, X., Xu, Q., and Lu, G., 2001, The crystal structure of bar-headed goose hemoglobin in deoxy form: The allosteric mechanism of a hemoglobin species with high oxygen affinity. J. Mol. Biol. 313: 123-137.
72. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C., and Parsons, R., 1997, Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16: 64-67.
73. Lin, T., Orrison, B. M., Leahey, A. M., Suchy, S. F., Bernard, D. J., Lewis, R. A., and Nussbaum, R. L., 1997, Spectrum of mutations in the OCRL1 gene in the Lowe oculocerebrorenal syndrome. Am. J. Hum. Genet. 60: 1384-1388.
74. Liu, Q., Shalaby, F., Jones, J., Bouchard, D., and Dumont, D. J., 1998, The SH2-containing inositol polyphosphate 5-phosphatase, ship, is expressed during hematopoiesis and spermatogenesis. Blood 91: 2753-2759.
75. Loewus, M. W., Loewus, F. A., Brillinger, G. U., Otsuka, H., and Floss, H. G., 1980, Stereochemistry of the myo-inositol-1-phosphate synthase reaction. J. Biol. Chem. 255: 11710-11712.
76. Lorenzon, N. M., and Beam, K. G., 2000, Calcium channelopathies. Kidney Int. 57: 794-802.
77. Lu, P. J., Shieh, W. R., and Chen, C. S., 1996, Antagonistic effect of inositol pentakisphosphate on inositol triphosphate receptors. Biochem. Biophys. Res. Commun. 220: 637-642.
78. Luckhoff, A., and Clapham, D. E., 1992, Inositol 1, 3, 4, 5-tetrakisphosphate activates an endothelial Ca(2+)-permeable channel. Nature 355: 356-358.
79. Luo, J., Manning, B. D., and Cantley, L. C., 2003, Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 4: 257-262.
80. Luo, J. M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., Naoe, T., Akao, Y., Ohno, R., and Ohnishi, K., 2003, Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17: 1-8.
81. Maehama, T., and Dixon, J. E., 1998, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 273: 13375-13378.
82. Maehama, T., Taylor, G. S., and Dixon, J. E., 2001, PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70: 247-279.
83. Majumder, A. L., Chatterjee, A., Ghosh Dastidar, K., and Majee, M., 2003, Diversification and evolution of L-myo-inositol 1-phosphate synthase. FEBS Lett. 553: 3-10.
84. Manji, H. K., Moore, G. J., and Chen, G., 1999, Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry 46: 929-940.
85. Marion, E., Kaisaki, P. J., Pouillon, V., Gueydan, C., Levy, J. C., Bodson, A., Krzentowski, G., Daubresse, J. C., Mockel, J., Behrends, J., Servais, G., Szpirer, C., Kruys, V., Gauguier, D., and Schurmans, S., 2002, The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 51: 2012-2017.
86. Marsh, D. J., Coulon, V., Lunetta, K. L., Rocca-Serra, P., Dahia, P. L., Zheng, Z., Liaw, D., Caron, S., Duboue, B., Lin, A. Y., Richardson, A. L., Bonnetblanc, J. M., Bressieux, J. M., Cabarrot-Moreau, A., Chompret, A., Demange, L., Eeles, R. A., Yahanda, A. M., Fearon, E. R., Fricker, J. P., Gorlin, R. J., Hodgson, S. V., Huson, S., Lacombe, D., and Eng, C., 1998, Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7: 507-515.
87. Martelli, A. M., Manzoli, L., and Cocco, L., 2004, Nuclear inositides: Facts and perspectives. Pharmacol. Ther. 101: 47-64.
88. Martin, T. F., 1998, Phosphoinositide lipids as signaling molecules: Common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu. Rev. Cell Dev. Biol. 14: 231-264.
89. Matsumoto, M., Nakagawa, T., Inoue, T., Nagata, E., Tanaka, K., Takano, H., Minowa, O., Kuno, J., Sakakibara, S., Yamada, M., Yoneshima, H., Miyawaki, A., Fukuuchi, Y., Furuichi, T., Okano, H., Mikoshiba, K., and Noda, T., 1996, Ataxia and epileptic seizures in mice lacking type 1 inositol 1, 4, 5-trisphosphate receptor. Nature 379: 168-171.
90. Mattson, M. P., LaFerla, F. M., Chan, S. L., Leissring, M. A., Shepel, P. N., and Geiger, J. D., 2000a, Calcium signaling in the ER: Its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 23: 222-229.
91. Mattson, M. P., Zhu, H., Yu, J., and Kindy, M. S., 2000b, Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: Involvement of perturbed calcium homeostasis. J. Neurosci. 20: 1358-1364.
92. McGeer, P. L., and McGeer, E. G., 1995, The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21: 195-218.
93. Mellstrom, B., and Naranjo, J. R., 2001, Mechanisms of Ca(2+)-dependent transcription. Curr. Opin. Neurobiol. 11: 312-319.
94. Menniti, F. S., Miller, R. N., Putney, J. W., Jr., and Shears, S. B., 1993, Turnover of inositol polyphosphate pyrophosphates in pancreatoma cells. J. Biol. Chem. 268: 3850-3856.
95. Missiaen, L., Robberecht, W., van den Bosch, L., Callewaert, G., Parys, J. B., Wuytack, F., Raeymaekers, L., Nilius, B., Eggermont, J., and De Smedt, H., 2000, Abnormal intracellular ca(2+)homeostasis and disease. Cell Calcium 28: 1-21.
96. Modiano, G., Bombieri, C., Ciminelli, B. M., Belpinati, F., Giorgi, S., Georges, M. D., Scotet, V., Pompei, F., Ciccacci, C., Guittard, C., Audrezet, M. P., Begnini, A., Toepfer, M., Macek, M., Ferec, C., Claustres, M., and Pignatti, P. F., 2004, A large-scale study of the random variability of a coding sequence: A study on the CFTR gene. Eur. J. Hum. Genet.
97. Monnier, N., Satre, V., Lerouge, E., Berthoin, F., and Lunardi, J., 2000, OCRL1 mutation analysis in French Lowe syndrome patients: Implications for molecular diagnosis strategy and genetic counseling. Hum. Mutat. 16: 157-165.
98. Moore, G. J., Bebchuk, J. M., Parrish, J. K., Faulk, M. W., Arfken, C. L., Strahl-Bevacqua, J., and Manji, H. K., 1999, Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am. J. Psychiatry 156: 1902-1908.
99. Morris, A. P., Gallacher, D. V., Irvine, R. F., and Petersen, O. H., 1987, Synergism of inositol trisphosphate and tetrakisphosphate in activating Ca2+-dependent K+ channels. Nature 330: 653-655.
100. Mouton, R., Huisamen, B., and Lochner, A., 1991, Increased myocardial inositol trisphosphate levels during alpha 1-adrenergic stimulation and reperfusion of ischaemic rat heart. J. Mol. Cell. Cardiol. 23: 841-850.
101. Murray, C. J. L., and Lopez, A. D. (eds.), 1996, The Global Burden of Disease. Harvard University Press, Cambridge, MA.
102. Naccarato, W. F., Ray, R. E., and Wells, W. W., 1974, Biosynthesis of myo-inositol in rat mammary gland. Isolation and properties of the enzymes. Arch. Biochem. Biophys. 164: 194-201.
103. Nakashima, N., Sharma, P. M., Imamura, T., Bookstein, R., and Olefsky, J. M., 2000, The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J. Biol. Chem. 275: 12889-12895.
104. Narrow, W. E., Rae, D. S., Robins, L. N., and Regier, D. A., 2002, Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys' estimates. Arch. Gen. Psychiatry 59: 115-123.
105. Nelen, M. R., van Staveren, W. C., Peeters, E. A., Hassel, M. B., Gorlin, R. J., Hamm, H., Lindboe, C. F., Fryns, J. P., Sijmons, R. H., Woods, D. G., Mariman, E. C., Padberg, G. W., and Kremer, H., 1997, Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6: 1383-1387.
106. Nishino, I., Minami, N., Kobayashi, O., Ikezawa, M., Goto, Y., Arahata, K., and Nonaka, I., 1998, MTM1 gene mutations in Japanese patients with the severe infantile form of myotubular myopathy. Neuromuscul. Disord. 8: 453-458.
107. Okada, T., Sakuma, L., Fukui, Y., Hazeki, O., and Ui, M., 1994, Blockage of chemotactic peptideinduced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J. Biol. Chem. 269: 3563-3567.
108. Olivos-Glander, I. M., Janne, P. A., and Nussbaum, R. L., 1995, The oculocerebrorenal syndrome gene product is a 105-kD protein localized to the Golgi complex. Am. J. Hum. Genet. 57: 817-823.
109. Ono, H., Katagiri, H., Funaki, M., Anai, M., Inukai, K., Fukushima, Y., Sakoda, H., Ogihara, T., Onishi, Y., Fujishiro, M., Kikuchi, M., Oka, Y., and Asano, T., 2001, Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol. Endocrinol. 15: 1411-1422.
110. Patterson, R. L., Boehning, D., and Snyder, S. H., 2004, Inositol 1, 4, 5-trisphosphate receptors as signal integrators. Annu. Rev. Biochem. 73: 437-465.
111. Pendaries, C., Tronchere, H., Plantavid, M., and Payrastre, B., 2003, Phosphoinositide signaling disorders in human diseases. FEBS Lett. 546: 25-31.
112. Pollack, S. J., Atack, J. R., Knowles, M. R., McAllister, G., Ragan, C. I., Baker, R., Fletcher, S. R., Iversen, L. L., and Broughton, H. B., 1994, Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. U. S. A. 91: 5766-5770.
113. Posternak, S., 1919, Sur la synthese de l' ether hexaphosphorique de l' inosite avec le principe phosphoorganique de reserve des plantes vertes. C. R. Acad. Sci. 169: 138-140.
114. Riekse, R. G., Leverenz, J. B., McCormick, W., Bowen, J. D., Teri, L., Nochlin, D., Simpson, K., Eugenio, C., Larson, E. B., and Tsuang, D., 2004, Effect of vascular lesions on cognition in Alzheimer's disease: A community-based study. J. Am. Geriatr. Soc. 52: 1442-1448.
115. Riera, M., Fuster, J. F., and Palacios, L., 1991, Role of erythrocyte organic phosphates in blood oxygen transport in anemic quail. Am. J. Physiol. 260: R798-R803.
116. Rudolf, M. T., Dinkel, C., Traynor-Kaplan, A. E., and Schultz, C., 2003, Antagonists of myo-inositol 3, 4, 5, 6-tetrakisphosphate allow repeated epithelial chloride secretion. Bioorg. Med. Chem. 11: 3315-3329.
117. Saltiel, A. R., and Kahn, C. R., 2001, Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806.
118. Sarnat, H. B., 1990, Myotubular myopathy: Arrest of morphogenesis of myofibres associated with persistence of fetal vimentin and desmin. Four cases compared with fetal and neonatal muscle. Can. J. Neurol. Sci. 17: 109-123.
119. Sattler, M., Verma, S., Byrne, C. H., Shrikhande, G., Winkler, T., Algate, P. A., Rohrschneider, L. R., and Griffin, J. D., 1999, BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell. Biol. 19: 7473-7480.
120. Sbrissa, D., Ikonomov, O. C., Strakova, J., and Shisheva, A., 2004, Role for a novel signaling intermediate, phosphatidylinositol 5-phosphate, in insulin-regulated F-actin stress fiber breakdown and GLUT4 translocation. Endocrinology 145: 4853-4865.
121. Selkoe, D. J., 1991, The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
122. Selkoe, D. J., 2001, Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81: 741-766.
123. Senderek, J., Bergmann, C., Weber, S., Ketelsen, U. P., Schorle, H., Rudnik-Schoneborn, S., Buttner, R., Buchheim, E., and Zerres, K., 2003, Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum. Mol. Genet. 12: 349-356.
124. Shaltiel, G., Shamir, A., Shapiro, J., Ding, D., Dalton, E., Bialer, M., Harwood, J. A., Belmaker, R. H., Greenberg, M. L., and Agam, G., in press, Valproate decreases inositol biosynthesis. Mol. Psychiatry.
125. Sharma, P. M., Egawa, K., Huang, Y., Martin, J. L., Huvar, I., Boss, G. R., and Olefsky, J. M., 1998, Inhibition of phosphatidylinositol 3-kinase activity by adenovirus-mediated gene transfer and its effect on insulin action. J. Biol. Chem. 273: 18528-18537.
126. Shepherd, P. R., Withers, D. J., and Siddle, K., 1998, Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling. Biochem. J. 333(Pt 3): 471-490.
127. Shulman, G. I., 2000, Cellular mechanisms of insulin resistance. J. Clin. Invest. 106: 171-176.
128. Silverstone, P. H., Wu, R. H., O'Donnell, T., Ulrich, M., Asghar, S. J., and Hanstock, C. C., 2002, Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Hum. Psychopharmacol. 17: 321-327.
129. Smith, P. M., Harmer, A. R., Letcher, A. J., and Irvine, R. F., 2000, The effect of inositol 1, 3, 4, 5-tetrakisphosphate on inositol trisphosphate-induced Ca2+ mobilization in freshly isolated and cultured mouse lacrimal acinar cells. Biochem. J. 347(Pt 1): 77-82.
130. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V., 1997, Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362.
131. Stephens, L., Radenberg, T., Thiel, U., Vogel, G., Khoo, K. H., Dell, A., Jackson, T. R., Hawkins, P. T., and Mayr, G. W., 1993, The detection, purification, structural characterization, and metabolism of diphosphoinositol pentakisphosphate(s) and bisdiphosphoinositol tetrakisphosphate(s). J. Biol. Chem. 268: 4009-4015.
132. Stephens, L. R., Hawkins, P. T., Stanley, A. F., Moore, T., Poyner, D. R., Morris, P. J., Hanley, M. R., Kay, R. R., and Irvine, R. F., 1991, myo-Inositol pentakisphosphates. Structure, biological occurrence and phosphorylation to myo-inositol hexakisphosphate. Biochem. J. 275(Pt 2): 485-499.
133. Streb, H., Irvine, R. F., Berridge, M. J., and Schulz, I., 1983, Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1, 4, 5-trisphosphate. Nature 306: 67-69.
134. Street, V. A., Bosma, M. M., Demas, V. P., Regan, M. R., Lin, D. D., Robinson, L. C., Agnew, W. S., and Tempel, B. L., 1997, The type 1 inositol 1, 4, 5-trisphosphate receptor gene is altered in the opisthotonos mouse. J. Neurosci. 17: 635-645.
135. Stutzmann, G. E., Caccamo, A., LaFerla, F. M., and Parker, I., 2004, Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J. Neurosci. 24: 508-513.
136. Suchy, S. F., and Nussbaum, R. L., 2002, The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization. Am. J. Hum. Genet. 71: 1420-1427.
137. Suchy, S. F., Olivos-Glander, I. M., and Nussabaum, R. L., 1995, Lowe syndrome, a deficiency of phosphatidylinositol 4, 5-bisphosphate 5-phosphatase in the Golgi apparatus. Hum. Mol. Genet. 4: 2245-2250.
138. Sylvia, V., Curtin, G., Norman, J., Stec, J., and Busbee, D., 1988, Activation of a low specific activity form of DNA polymerase alpha by inositol-1, 4-bisphosphate. Cell 54: 651-658.
139. Tang, T. S., Tu, H., Chan, E. Y., Maximov, A., Wang, Z., Wellington, C. L., Hayden, M. R., and Bezprozvanny, I., 2003, Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron 39: 227-239.
140. Tanner, S. M., Schneider, V., Thomas, N. S., Clarke, A., Lazarou, L., and Liechti-Gallati, S., 1999, Characterization of 34 novel and six known MTM1 gene mutations in 47 unrelated X-linked myotubular myopathy patients. Neuromuscul. Disord. 9: 41-49.
141. Tantivejkul, K., Vucenik, I., Eiseman, J., and Shamsuddin, A. M., 2003, Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. Breast Cancer Res. Treat. 79: 301-312.
142. Taylor, G. S., Maehama, T., and Dixon, J. E., 2000, Inaugural article: Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc. Natl. Acad. Sci. U. S. A. 97: 8910-8915.
143. Toker, A., 2002, Phosphoinositides and Signal Transduction.
144. Tonner, P. H., Scholz, J., Richter, A., Loscher, W., Steinfath, M., Wappler, F., Wlaz, P., Hadji, B., Roewer, N., and Schulte am Esch, J., 1995, Alterations of inositol polyphosphates in skeletal muscle during porcine malignant hyperthermia. Br. J. Anaesth. 75: 467-471.
145. Tsubokawa, H., Oguro, K., Robinson, H. P., Masuzawa, T., and Kawai, N., 1996, Intracellular inositol 1, 3, 4, 5-tetrakisphosphate enhances the calcium current in hippocampal CA1 neurones of the gerbil after ischaemia. J. Physiol. 497(Pt 1): 67-78.
146. Tsujita, K., Itoh, T., Ijuin, T., Yamamoto, A., Shisheva, A., Laporte, J., and Takenawa, T., 2004, Myotubularin regulates the function of the late endosome through the gram domainphosphatidylinositol 3, 5-bisphosphate interaction. J. Biol. Chem. 279: 13817-13824.
147. Ueki, K., Yamamoto-Honda, R., Kaburagi, Y., Yamauchi, T., Tobe, K., Burgering, B. M., Coffer, P. J., Komuro, I., Akanuma, Y., Yazaki, Y., and Kadowaki, T., 1998, Potential role of protein kinase B in insulin-induced glucose transport, glycogen synthesis, and protein synthesis. J. Biol. Chem. 273: 5315-5322.
148. Ungewickell, A. J., and Majerus, P. W., 1999, Increased levels of plasma lysosomal enzymes in patients with Lowe syndrome. Proc. Natl. Acad. Sci. U. S. A. 96: 13342-13344.
149. Ungewickell, A., Ward, M. E., Ungewickell, E., and Majerus, P. W., 2004, The inositol polyphosphate 5-phosphatase Ocrl associates with endosomes that are partially coated with clathrin. Proc. Natl. Acad. Sci. U. S. A. 101: 13501-13506.
150. Vaden, D. L., Ding, D., Peterson, B., and Greenberg, M. L., 2001, Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J. Biol. Chem. 276: 15466-15471.
151. Vajanaphanich, M., Schultz, C., Rudolf, M. T., Wasserman, M., Enyedi, P., Craxton, A., Shears, S. B., Tsien, R. Y., Barrett, K. E., and Traynor-Kaplan, A., 1994, Long-term uncoupling of chloride secretion from intracellular calcium levels by Ins(3, 4, 5, 6)P4. Nature 371: 711-714.
152. Vivanco, I., and Sawyers, C. L., 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501.
153. Voglmaier, S. M., Bembenek, M. E., Kaplin, A. I., Dorman, G., Olszewski, J. D., Prestwich, G. D., and Snyder, S. H., 1996, Purified inositol hexakisphosphate kinase is an ATP synthase: Diphosphoinositol pentakisphosphate as a high-energy phosphate donor. Proc. Natl. Acad. Sci. U. S. A. 93: 4305-4310.
154. Vucenik, I., and Shamsuddin, A. M., 2003, Cancer inhibition by inositol hexaphosphate (IP6) and inositol: From laboratory to clinic. J. Nutr. 133: 3778S-3784S.
155. Wappler, F., Scholz, J., Kochling, A., Steinfath, M., Krause, T., and Schulte am Esch, J., 1997, Inositol 1, 4, 5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia. Br. J. Anaesth. 78: 541-547.
156. Warsh, J. J., Politsky, J. M., Li, P. P., Kish, S. J., and Hornykiewicz, O., 1991, Reduced striatal [3H]inositol 1, 4, 5-trisphosphate binding in Huntington's disease. J. Neurochem. 56: 1417-1422.
157. Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., and Roberts, T. M., 1985, Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315: 239-242.
158. Williams, R. S., Cheng, L., Mudge, A. W., and Harwood, A. J., 2002, A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
159. Wishart, M. J., Taylor, G. S., Slama, J. T., and Dixon, J. E., 2001, PTEN and myotubularin phosphoinositide phosphatases: Bringing bioinformatics to the lab bench. Curr. Opin. Cell Biol. 13: 172-181.
160. Woodcock, E. A., 1997, Inositol phosphates and inositol phospholipids: How big is the iceberg? Mol. Cell. Endocrinol. 127: 1-10.
161. Woodcock, E. A., Lambert, K. A., and Du, X. J., 1996, Ins(1, 4, 5)P3 during myocardial ischemia and its relationship to the development of arrhythmias. J. Mol. Cell. Cardiol. 28: 2129-2138.
162. Woodcock, E. A., Lambert, K. A., Phan, T., and Jacobsen, A. N., 1997, Inositol phosphate metabolism during myocardial ischemia. J. Mol. Cell. Cardiol. 29: 449-460.
163. Yamamoto, K., Hashimoto, K., Nakano, M., Shimohama, S., and Kato, N., 2002, A distinct form of calcium release down-regulates membrane excitability in neocortical pyramidal cells. Neuroscience 109: 665-676.
164. Ye, W., Ali, N., Bembenek, M. E., Shears, S. B., and Lafer, E. M., 1995, Inhibition of clathrin assembly by high affinity binding of specific inositol polyphosphates to the synapse-specific clathrin assembly protein AP-3. J. Biol. Chem. 270: 1564-1568.
165. York, J. D., Guo, S., Odom, A. R., Spiegelberg, B. D., and Stolz, L. E., 2001, An expanded view of inositol signaling. Adv. Enzyme Regul. 41: 57-71.
166. York, J. D., Odom, A. R., Murphy, R., Ives, E. B., and Wente, S. R., 1999, A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285: 96-100.
167. York, J. D., Saffitz, J. E., and Majerus, P. W., 1994, Inositol polyphosphate 1-phosphatase is present in the nucleus and inhibits DNA synthesis. J. Biol. Chem. 269: 19992-19999.
168. Zecevic, N., Milosevic, A., and Ehrlich, B. E., 1999, Calcium signaling molecules in human cerebellum at midgestation and in ataxia. Early Hum. Dev. 54: 103-116.
169. Zhang, X., Hartz, P. A., Philip, E., Racusen, L. C., and Majerus, P. W., 1998, Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4, 5-bisphosphate. J. Biol. Chem. 273: 1574-1582.
170. Zhang, X., Jefferson, A. B., Auethavekiat, V., and Majerus, P. W., 1995, The protein deficient in Lowe syndrome is a phosphatidylinositol-4, 5-bisphosphate 5-phosphatase. Proc. Natl. Acad. Sci. U. S. A. 92: 4853-4856.